Please assess the completion status of the following clinical trial:

Trial Title: SAFE-LCD Trial, for Insulin-treated Adults Living With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Registered with a GP practice within the confirmed NHS site - Humber and North Yorkshire~* Diagnosis of type 2 diabetes treated with insulin~* Age 18-70 years inclusive~* BMI ≥30kg/m² (adjusted to ≥27 kg/m² in ethnic minority groups)~* Upper body weight limit of 180kg (if using BodyTrace scales)~* Ability to speak, read and receive care in English language~* Access to the internet and a personal email address~* Access to and ability to use a smartphone~* Willing to test blood glucose up to 7 times a day (for up to 4 months) to ensure clinical safety.~* Participants capable to provide written informed consent and willing to comply with the trial protocol~Exclusion Criteria:~* C-peptide \<200 pmol/L AND positive Glutamic Acid Decarboxylase(GAD) antibodies assessing for misdiagnosed Type 1 diabetes and risk of diabetic ketoacidosis.~* Type 1 diabetes mellitus, Mitochondrial diabetes, Maturity-Onset Diabetes of the Young (MODY) diabetes or diagnostic uncertainty (e.g. dual codes on patient record) Type 2 diabetes with history of diabetic ketoacidosis (DKA) or ketosis prone~* Clinically assessed hypoglycemia unawareness (via GOLD score (11, 12))~* Concomitant medication use clinically deemed to affect metabolic rate and body weight~* A major cardiovascular event within 6 months~* Severe angina, uncontrolled arrhythmia or known prolonged QT syndrome~* Warfarin or Rivaroxoban therapy~* Estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73m²~* A condition precipitating fluid overload (e.g. New York Heart Association class III-IV congestive heart failure)~* Active liver disease (except non-alcoholic fatty liver disease (NAFLD)~* Active gallstone disease or known presence of gallstones~* Active cancer, receiving cancer treatment or received cancer treatment within past 24 months~* Known proliferative retinopathy that has not been treated~* Uncontrolled epilepsy~* Uncontrolled thyroid dysfunction~* Active or suspected peptic ulcer disease~* Gout~* History of bariatric surgery (previous band/balloon allowed if removed\<12 months)~* Clinically diagnosed with an active eating disorder~* Clinically significant diagnosed/self-reported psychiatric disease that may interfere with study compliance~* Known or suspected alcohol or recreational drug misuse~* Milk allergy (Nualtra, TDR allergens)~* Soya allergy (Nualtra, TDR allergens)~* Vegan (Nualtra, animal derived Vit D)~* Pregnancy or planning pregnancy within study period~* Lactating~* Currently on a weight management programme or had in last 3 months or had over 5% weight loss in previous 6 months~* Current participation in other clinical intervention trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intervention (Oviva ODR-I programme) (Type: EXPERIMENTAL): The intervention arm will follow Oviva ODR-I programe: a 12-week TDR of approximately 850 calories per day through four TDR products daily, supported by the digital scales, CBG meters and link to the OVIVA app.
- Control (NHS 12 weeks programme) (Type: ACTIVE_COMPARATOR): The control group will follow usual care, which will be the NHS 12-week digital weight-loss programme

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues